|Articles|October 1, 2001
- Pharmaceutical Executive-10-01-2001
- Volume 0
- Issue 0
Illegal Sales in India
Author(s)Kevin Gopal
Mumbai, India—The controversy over pharma companies’ incentives to pharmacists in India highlights just how competitive the Indian pharma industry has become.
Advertisement
Articles in this issue
over 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
PBMs: Merck-Medco in the Hot Seatover 24 years ago
National Crisis Supercedes Coverage Debateover 24 years ago
A Five-Year Forecast: Clear Seas Ahead?over 24 years ago
Weak Bones, Strong Marketover 24 years ago
Approvals: Novartis’ Silver Liningover 24 years ago
Pfizer and others Pitch Inover 24 years ago
Oncology: EMEA Approval Lagsover 24 years ago
Health Plan Premiums: Pharma Takes the Blameover 24 years ago
Little Elan Becomes a Big DealAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5